NEURACAP
Sector ReportSep 28, 2026 · 21 pages · Free to read

Generic and Non-Prescription Drugs Sector Outlook — September 2026

A sector outlook on Generic and Non-Prescription Drugs, covering public market valuation across complex generics, branded off-patent and consumer self-care segments, precedent transactions, and the growth-margin dynamics separating the top and bottom of the range.

Download PDFDownload PowerPoint

Key figures

7.5x
Sector median EV / EBITDA (CY2027E)
7 of 10 companies rated
12.3x
Top-tier multiple
two names at top of range
6.9x
Bottom-tier multiple
one name at bottom of range
13.6x
Highest disclosed precedent multiple
Haleon plc

Read the report

C:\Users\dawoo\OneDrive\Desktop\Deployments\neuracap_sector_reports_fable\Code\NeuraCap_Sector_Report_Pipeline_v2.1.0\ncsr\deck_kit\assets\logo_light_full.png

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS

Generic and Non-Prescription Drugs: Three Price Tiers

How the market is pricing complex generics, branded off-patent portfolios and consumer self-care across this peer set, and what separates the top of the range from the bottom.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice

1

1 / 21

Executive summary

Generic and Non-Prescription Drugs prices in three tiers: across the 7 of 10 companies with a forward EV / EBITDA estimate for CY2027E, the sector median sits at 7.5x, with two names at the top at 12.3x and one at the bottom at 6.9x. Complex generics manufacturers make up most of the names in this set, and the higher public multiples sit with faster-growing, thinner-margin names, while consumer self-care assets draw the higher disclosed multiples in the precedent record. This report sets out where each segment sits and what separates the top of the range from the bottom.

Key findings

  • Sector prices in three tiers: 12.3x at the top, 7.5x median, 6.9x at the bottom
  • Faster-growing names carry higher multiples but thinner EBITDA margins
  • Complex generics manufacturers hold most of the names in this universe
  • Consumer self-care assets draw the highest disclosed precedent deal multiples

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS

    Cover slide introducing the September 2026 Generic and Non-Prescription Drugs sector outlook.

    We open this outlook on Generic and Non-Prescription Drugs with market data as of 2026-09-28, valued primarily on EV / EBITDA for CY2027E. The pages that follow show where this market is pricing risk and growth, and why the range separates the way it does.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS Generic and Non-Prescription Drugs: Three Price Tiers How the market is pricing complex generics, branded off-patent portfolios and consumer self-care across this peer set, and what separates the top of the range from the bottom. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    Contents page listing the report's five sections plus the appendix.

    We've structured this report so the bottom line comes first: section one carries the full conclusion on its own page. From there we walk through the market map, valuation and situations, precedent transactions and strategic implications, with the complete comparables and methodology in the appendix. A reader pressed for time can stop after section one and still leave with the whole story.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line The Structure Behind the Price in Generic and Non-Prescription Drugs 02 The Landscape Complex Generics Account for Seven of the Ten Names on This Page 03 Valuation & Situations Two Names Hold the Top of This Range, and One Sits at the Bottom 04 Precedent Transactions Consumer Self-Care Assets Draw the Higher Disclosed Multiples 05 Strategic Implications What This Range Rewards, and What Sits at the Bottom of It 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Generic and Non-Prescription Drugs Is Priced in Three Tiers, and Complex Generics Hold Most of the Set

    The bottom-line page showing the sector priced in three tiers, with complex generics holding most of the set.

    We find this sector prices in three tiers on EV / EBITDA for CY2027E, drawn from the 7 of 10 companies carrying a forward estimate. Complex generics manufacturers hold most of the names in this set, so the pricing conversation runs through plant capability and filings as much as through brand. The names at the top of the range combine faster forward growth with thinner margins, which is the trade this market is making. That's the finding the rest of this report builds out in detail.

    Everything on this page

    01 · THE BOTTOM LINE Generic and Non-Prescription Drugs Is Priced in Three Tiers, and Complex Generics Hold Most of the Set The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Two Ends of This Set Are Priced on Different Terms Across the 7 of the 10 companies with a forward estimate, the middle of the range sits at 7.5x forward EV / EBITDA for CY2027E. The 2 names at the top of the range sit at 12.3x, and the single name at the bottom sits at 6.9x. 2 The Higher Prices Sit with the Faster Growers Split at 5% forward growth, the 4 faster-growing names of the 7 with a forward estimate sit at 9.0x, against 7.4x for the other 3. Both names at the top of the range run EBITDA margins below the covered middle, so buyers are accepting thinner margins alongside faster forward growth. 3 Complex Generics Are the Centre of Gravity Here Specialty and complex generics manufacturers are 7 of the 10 companies on this page, 70% of the set, and 6 of them carry a forward estimate. Branded off-patent and prescription portfolios are 2 names at 20%, and consumer self-care brands are a single name at 10%, so the pricing conversation runs from plant and filings capability to shelf position. 4 Consumer Self-Care Brands Draw the Higher Deal Multiples Across the 9 transactions shown here, consumer self-care assets carry the higher disclosed EV / EBITDA marks, with Haleon plc recorded at 13.6x. The Opella Healthcare SAS (Sanofi Consumer Health Business) carve-out to Clayton, Dubilier & Rice LLC was recorded at 8.8x, which is where that sponsor separation from a prescription parent was agreed. 7.5x Sector median EV/EBITDA CY2027E consensus · 7 rated of 10 companies 12.3x Premium end EV/EBITDA vs 6.9x at the discount end top quartile (n=2) against bottom quartile (n=1) on EV/EBITDA — the spread the report explains 25 Transactions with disclosed terms 54 recorded in this tier · 1 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Section divider introducing the market map: three groups within one sector label.

    We use this page to reset before mapping the sector into its three groups, complex generics, branded off-patent, and consumer self-care, and what buyers look at in each.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Complex Generics Account for Seven of the Ten Names on This Page Three groups, who sits in each, and what buyers examine in each. 02 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    One Sector Label Covers Three Groups with Different Scale, Growth and Margin Profiles

    Market map grouping the ten approved companies into three segments by median EV / EBITDA.

    We group the approved universe into three segments here, each with a different scale, growth and margin profile, and each with its own median EV / EBITDA on the CY2027E basis. Complex generics carries the largest share of names in this set. Branded off-patent and consumer self-care sit alongside it with smaller counts, and each group's median tells a different story about how the market prices it. Understanding which group a business sits in is the first step in reading its multiple.

    Everything on this page

    02 · MARKET MAP One Sector Label Covers Three Groups with Different Scale, Growth and Margin Profiles 10 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 SPECIALTY AND COMPLEX GENERICS MANUFACTURERS 7 cos median 9.0x Teva (TEVA) Viatris (VTRS) Dr. Reddy's (RDY) Amneal (AMRX) Perrigo Company (PRGO) Regencell (RGC) Amphastar (AMPH) The manufacturing and filings engine of the sector: dosage-form capability, sterile injectable capacity and launch cadence are what buyers examine first. BRANDED OFF-PATENT AND PRESCRIPTION GENERIC PORTFOLIOS 2 cos 6.9x · 1 rated Liquidia (LQDA) Prestige (PBH) Recurring earnings on established molecules, where durability against base business erosion and loss of exclusivity is the live question. CONSUMER SELF-CARE AND PERSONAL CARE BRAND PORTFOLIOS 1 cos no rated names Kenvue (KVUE) Shelf position, monograph protection and Rx-to-OTC switch optionality, priced closer to consumer staples than to filings and plants.

  6. 06
    02 · LANDSCAPE

    Complex Generics Carry Most of the Names, and Most of the Estimates

    Landscape view showing complex generics carrying most of the names and most of the covered estimates.

    We show here that complex generics carries most of the names in this universe, and most of the estimates that back a forward multiple. That concentration is why the sector-level median leans on this group's characteristics more than any other. The appendix carries the full company-level detail behind this view for anyone who wants to trace a specific name.

    Everything on this page

    02 · LANDSCAPE Complex Generics Carry Most of the Names, and Most of the Estimates Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Specialty and complex generics manufacturers 7 70% 9.0x Teva Pharmaceutical Industries Limited (TEVA) · Viatris Inc. (VTRS) · +5 more Seven names, the sector core. ANDA portfolios, sterile injectable and fill-finish capacity and complex dosage forms sit in this group, which is 70% of the set here. Six of the seven carry a forward estimate, so this group shapes most of what the valuation page shows. Branded off-patent and prescription generic portfolios 2 20% 6.9x n=1 Liquidia Corporation (LQDA) · Prestige Consumer Healthcare Inc. (PBH) Two names, recurring earnings. Branded off-patent and prescription portfolios are 20% of the set, and one of the two carries a forward estimate, so read this group's pricing as a single name rather than a band. Diligence here turns on how durable the earnings base looks as additional filers arrive. Consumer self-care and personal care brand portfolios 1 10% — Kenvue Inc. (KVUE) One name, consumer staples logic. A single name, 10% of the set, without a forward EBITDA estimate in this data. The transaction record is where this group's pricing shows up, and it is where the disclosed EBITDA marks on this page are concentrated.

  7. 07
    SECTION 03

    03

    Section divider introducing public market valuation: two names hold the top of the range, one sits at the bottom.

    We turn now to valuation itself: all 10 companies appear on this page, and 7 of them carry a forward EV / EBITDA estimate for CY2027E.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS Two Names Hold the Top of This Range, and One Sits at the Bottom All 10 companies appear; 7 carry a forward EV / EBITDA estimate for CY2027E. 03 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Two Names Hold the Top of This Range, and They Are the Faster Growers

    Ranked view of all rated companies on EV / EBITDA for CY2027E against the sector median.

    We rank the 7 rated companies here on EV / EBITDA for CY2027E, against a sector median of 7.5x. Two names hold the top of this range, and they are the faster growers in this set. The tier zones on this page are cut at the rated set's quartiles, so they show where each name sits relative to its peers on a like-for-like basis. That separation between the top and the rest is the starting point for the driver analysis on the following page.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Two Names Hold the Top of This Range, and They Are the Faster Growers EV / EBITDA (CY2027E) · all 7 rated companies, sorted descending · sector median 7.5x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 12.3x CORE · median 7.5x DISCOUNT · median 6.9x Sector median 7.5x WHAT SEPARATES THE TWO ENDS The top end sits at 12.3x. The 2 names at the top of the range sit at 12.3x forward EV / EBITDA for CY2027E, against 6.9x for the single name at the bottom of the range. A forward multiple already credits the growth in the estimates, so a premium that survives it points to durability rather than a one-year launch effect. Growth sits at the top end. Dr. Reddy's Laboratories Limited (RDY) carries 16% forward growth and Amneal Pharmaceuticals, Inc. (AMRX) 9%, and both run EBITDA margins below the covered middle at 22% and 24%. The pairing is association rather than proof, but buyers at this end are accepting thinner margins alongside faster forward growth. Margin alone did not price it. Prestige Consumer Healthcare Inc. (PBH) runs a 33% EBITDA margin with 12% forward growth and still sits at the bottom of this range, on a base of one name. Its earnings come from branded off-patent and prescription portfolios, where the market is weighing how long that base holds.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 26% Margin Line Carry 7.5x Against 10.6x Below It

    Cohort analysis splitting the rated set by growth and by margin to show what separates the top and bottom of the range.

    We split the rated set into cohorts by growth and by margin here, each cut at its own covered median. Names above the 26% margin line carry 7.5x, against 10.6x below it, an association we read from the covered data rather than a claim of cause. Growth tells a similar story: the faster-growing names sit at a different level than the slower ones. Together these cuts explain why the top of the price range and the bottom of the margin range overlap in this set.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 26% Margin Line Carry 7.5x Against 10.6x Below It Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=3; higher-margin n=4; lower-margin n=3). Driver readings are NeuraCap views on the supplied data — association, not causation. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 5% · EBITDA-margin split at 26% The Faster-Growing Group Sits at 9.0x, the Slower Group at 7.4x Split at 5% forward growth, the 4 faster-growing names of the 7 with a forward estimate carry a median of 9.0x, against 7.4x for the other 3. On a CY2027E lens the forecast is already inside the price, so the gap is about how durable that growth is judged to be. Margin on Its Own Does Not Separate the Middle of the Set Viatris Inc. (VTRS) runs a 30% EBITDA margin and Perrigo Company plc (PRGO) 18%, and both sit in the Core tier. Profitability matters to the earnings buyers underwrite, but within this set it is not what marks out the top of the range. Dosage-Form Complexity and Inspection Record Are Diligence Gates Buyers in this sector examine sterile injectable and fill-finish capability, first-to-file and exclusivity timing, and site inspection history before price is settled. This data does not measure those inputs; the deal conventions here put them early in the process, and quality findings can change what a plant contributes. Buying Consortia Sit Between the Plant and the Pharmacy Shelf Award economics in the prescription channel are negotiated with a small number of purchasing groups, and gross-to-net deductions and shelf-stock adjustments are where quality-of-earnings work concentrates. Customer concentration is therefore part of the earnings quality any multiple is applied to.

  10. 10
    03 · SITUATION MAP

    The Names at the Top of the Price Range Carry Margins Below the Middle of the Set

    Situation map cutting the rated set on valuation against margin relative to the sector medians.

    We cut the rated set here on EV / EBITDA against the sector median of 7.5x, and on EBITDA margin against the covered median of 26%. The names at the top of the price range carry margins below the middle of the set, an observation this page frames without recommending any position. Reading valuation and margin together like this locates each name inside the sector's own logic. That framing carries through into the agenda on the next page.

    Everything on this page

    03 · SITUATION MAP The Names at the Top of the Price Range Carry Margins Below the Middle of the Set Cut on EV / EBITDA vs the sector median (7.5x) (rows) and EBITDA margin vs the covered median (26%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced up, Margin Behind It Above-median multiple · above-median EBITDA margin 2 names Teva Pharmaceutical Industries Limited (TEVA) · Amphastar Pharmaceuticals, Inc. (AMPH) Teva Pharmaceutical Industries Limited (TEVA) and Amphastar Pharmaceuticals, Inc. (AMPH) sit above the 7.5x middle of the set on forward EV / EBITDA and above the 26% covered middle on EBITDA margin. Both are specialty and complex generics manufacturers, where injectable and complex dosage-form mix is what buyers examine first. Priced up on Forward Growth Above-median multiple · below-median EBITDA margin 2 names Dr. Reddy's Laboratories Limited (RDY) · Amneal Pharmaceuticals, Inc. (AMRX) Dr. Reddy's Laboratories Limited (RDY) and Amneal Pharmaceuticals, Inc. (AMRX) hold the top of the price range with EBITDA margins below the covered middle. Their forward estimates carry growth above the split used on the drivers page, and the market is pricing that ahead of current profitability. Margin Without the Multiple Below-median multiple · above-median EBITDA margin 2 names Viatris Inc. (VTRS) · Prestige Consumer Healthcare Inc. (PBH) Viatris Inc. (VTRS) and Prestige Consumer Healthcare Inc. (PBH) run margins above the covered middle while sitting below the middle of the price range. For an owner in this position, the working question is how the earnings base is judged against base business erosion and loss of exclusivity. Below the Middle on Both Below-median multiple · below-median EBITDA margin 1 names Perrigo Company plc (PRGO) Perrigo Company plc (PRGO) sits below the middle on both price and margin, with 0% forward growth in the estimates. Mix is the live issue here: which products hold shelf and pricing, and which are exposed to erosion in the base portfolio.

  11. 11
    03 · THE AGENDA

    The Question Ahead Is How to Allocate Capacity, Capital and Brand Investment

    Framing page turning the valuation and margin analysis into the questions an owner or acquirer should resolve.

    We frame the questions this data puts on the table here: how to allocate capacity, capital and brand investment given where a business sits in this set. These are observations grounded in the cohort data shown earlier, not recommendations. The choice between complex-dosage investment, brand defence and capital discipline runs differently depending on which tier a business occupies. That's the agenda the rest of this report speaks to.

    Everything on this page

    03 · THE AGENDA The Question Ahead Is How to Allocate Capacity, Capital and Brand Investment NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Move Mix Toward Dosage Forms Few Can Replicate Complex generics, sterile injectable and fill-finish work and biosimilars with interchangeability limit the number of credible filers and change the growth line the forward estimates pick up. Commodity oral-solid concentration pulls the other way. What changes the answer: A filing or approval in a complex dosage form where the credible filer count is low. Treat the Quality Record as a Pricing Variable Inspection outcomes, impurity findings and single-site dependency on a key earner can remove supply and value quickly. Dual-sourced critical APIs and a clean history at the plants carrying the earnings are what buyers test before they argue about adjusted EBITDA. What changes the answer: An observation, warning letter or import alert at a site behind a top earner. Defend the Brand Positions That Hold Shelf On the consumer self-care side, monograph protection, retail consumption trends and marketing support carry the earnings, and Rx-to-OTC switch optionality on an established molecule can extend a franchise well beyond an exclusivity period. What changes the answer: A change in distribution or consumption trend at a major retail customer. Decide Build Versus Buy on Capacity and Geography The record here shows consumer carve-outs from prescription parents and generics platforms changing hands, from Opella Healthcare SAS (Sanofi Consumer Health Business) to Sandoz. Adding a plant, a dosage form or regulated-market access by acquisition competes with building it internally. What changes the answer: A non-core plant or tail-brand portfolio coming out of a restructuring seller.

  12. 12
    SECTION 04

    04

    Section divider introducing precedent transactions: consumer self-care assets draw the higher disclosed multiples.

    We move next to the deal record: nine transactions with disclosed terms sit in this section, and where those disclosed marks land.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Consumer Self-Care Assets Draw the Higher Disclosed Multiples Nine transactions in the record, and where the disclosed marks land. 04 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    Precedent Transactions Here Set the Benchmark on Agreed Price, Carve-Outs Included

    Case-study page walking through disclosed precedent transactions and the multiples they carried.

    We tell the precedent record as case studies here, starting with disclosed terms and the multiples on LTM financials at announcement. Consumer self-care assets carry the higher marks in this record, with Haleon plc recorded at 13.6x. The Opella Healthcare SAS carve-out to Clayton, Dubilier & Rice LLC was recorded at 8.8x, the level at which that sponsor separation from a prescription parent was agreed. These deal multiples sit on a different basis than the CY2027E public multiples elsewhere in this report, so we don't read a spread between them.

    Everything on this page

    04 · DEAL CASE STUDIES Precedent Transactions Here Set the Benchmark on Agreed Price, Carve-Outs Included 1 of 25 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 63 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 29 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Nov-2025 $48.7B Kimberly-Clark Corporation Kimberly-Clark Corporation goes after a whole consumer self-care platform in Kenvue Inc. (KVUE). EV / LTM revenue 3.2x EV / LTM EBITDA 14.3x WHY THE DEAL HAPPENED Kimberly-Clark Corporation is a consumer products buyer and Kenvue Inc. (KVUE) is a consumer self-care and personal care brand portfolio, so the transaction reads as a move for shelf position, category breadth and marketing scale rather than for a prescription pipeline. At this size the buyer is taking on a whole platform, not a tail-brand bolt-on. HOW THE TARGET WAS VALUED The filing records $48.7B of enterprise value, struck at 3.2x LTM revenue.

  14. 14
    SECTION 05

    05

    Section divider introducing strategic implications: what this range rewards, and what sits at the bottom of it.

    We close the analysis here with the operating moves that change where a business stands in this set.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS What This Range Rewards, and What Sits at the Bottom of It Operating moves that change where a business stands in this set. 05 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    Faster Growth and Thinner Margins Travel Together at the Top of This Range

    Strategic implications page linking faster growth and thinner margins at the top of the valuation range to the questions this puts to owners, boards, acquirers and capital allocators.

    We find that faster growth and thinner margins travel together at the top of this range, which puts different questions to different audiences. For owners, the question is where the next launch cohort comes from; for boards, it's protecting the earnings base that any multiple gets applied to. For acquirers, the record shows corporate separations recurring as a route into this sector, and for capital allocators, debt service competes with pipeline spend for the same cash. These are observations drawn from the analysis in this report, not recommendations.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Faster Growth and Thinner Margins Travel Together at the Top of This Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Mix Is the Line the Forward Estimates Read The names at the top of the range carry faster forward growth with thinner margins, so the question for management is where the next launch cohort comes from: complex dosage forms, biosimilars with channel access, or brands with switch optionality. Trimming commodity exposure changes what the estimates carry. FOR BOARDS Quality and Legal Overhang Sit Inside the Multiple Inspection outcomes, impurity findings and litigation and settlement obligations are examined before price in this sector. Protecting the earnings base — clean critical sites, dual-sourced APIs, diversification away from a single buying consortium — protects the number any multiple is applied to. FOR ACQUIRERS Carve-Outs Are Where the Supply Has Been Corporate separations of consumer self-care from prescription operations recur through this record. Buyers with a view on transitional services, supply agreements and marketing-authorisation transfer can move on assets that trade as asset deals, where timetable is set by site transfer and contract novation as much as by price.

  16. 16
    SECTION 06

    06

    06.

    Section 06 of 06 — The Full Universe, Methodology and Sources. Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 16

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    Comparables table of the rated companies on EV / EBITDA for CY2027E, grouped by valuation tier.

    We lay out the comparables table here, with shading marking names above and below the sector median of 7.5x. Seven companies carry a rated multiple; three do not have an eligible EV / EBITDA and are listed separately. This table is the source data behind the ranked view earlier in the report. Anyone wanting to trace a specific name's basis can start here.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (7.5x); amber marks below · 7 rated companies; 3 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 7 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥10.5x · median 12.3x · 2 companies Dr. Reddy's Laboratories Limited RDY Specialty and complex generics manufacturers $10.3B 14.0x 16% 22% 35 Amneal Pharmaceuticals, Inc. AMRX Specialty and complex generics manufacturers $8.9B 10.6x 9% 24% 34 CORE — 7.4x–10.5x · median 7.5x · 4 companies Teva Pharmaceutical Industries Limited TEVA Specialty and complex generics manufacturers $58.4B 10.5x 5% 26% 37 Amphastar Pharmaceuticals, Inc. AMPH Specialty and complex generics manufacturers $1.6B 7.5x 5% 29% 32 Viatris Inc. VTRS Specialty and complex generics manufacturers $34.1B 7.4x 2% 30% 32 Perrigo Company plc PRGO Specialty and complex generics manufacturers $5.5B 7.4x 1% 18% 19 DISCOUNT — <7.4x · median 6.9x · 1 companies Prestige Consumer Healthcare Inc. PBH Branded off-patent and prescription generic portfolios $3.2B 6.9x 12% 33% 46

  18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    First page of the full precedent transaction list with disclosed terms, newest first.

    We list the transactions with disclosed terms here, newest first, with multiples on LTM financials at announcement where disclosed. Twenty-five transactions carry disclosed terms in this tier, out of a larger recorded set. Deal multiples on this basis are not directly comparable to the CY2027E public multiples used elsewhere in this report. The remaining transactions continue on the following page.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 25 transactions with disclosed terms in this tier (54 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 63 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 29 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 25 transactions shown; the rest are in the companion workbook. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Mar-2026 Prestige Consumer Healthcare Inc. → Breathe Right n/a n/a 11.0x Prestige Consumer Healthcare Inc. (PBH) completed the purchase of Breathe Right in March 2026 at 11.0x EV / EBITDA. It is the classic consolidator move on a single consumer self-care franchise: shelf position and marketing scale added to an existing brand platform. Nov-2025 Kimberly-Clark Corporation → Kenvue Inc. $48.7B 3.2x 14.3x Kimberly-Clark Corporation agreed to acquire Kenvue Inc. (KVUE) in November 2025 at $48.7B, recorded at 3.2x EV / Revenue and 14.3x EV / EBITDA. Announced in the record, it is the reference point on this page for a whole-company consumer self-care asset. Nov-2025 n/a → Reckitt Benckiser Group PLC n/a n/a 12.6x Reckitt Benckiser Group PLC is recorded in November 2025 at 12.6x EV / EBITDA. It sits in the same band as the other consumer self-care assets here, which is where buyer competition for branded shelf positions has been concentrated. Nov-2025 n/a → Haleon plc n/a n/a 13.6x Haleon plc is recorded in November 2025 at 13.6x EV / EBITDA. Brands with monograph protection and international distribution are being marked closer to consumer staples than to prescription generics. Nov-2025 n/a → Haleon plc n/a n/a 13.6x A second record for Haleon plc in November 2025, carrying the same EV / EBITDA marker. Repeat appearances of one target point to sustained buyer attention on large consumer self-care platforms. Oct-2024 Clayton, Dubilier & Rice LLC → Opella Healthcare SAS (Sanofi Consumer Health Business) n/a 0.7x 8.8x Clayton, Dubilier & Rice LLC completed the purchase of Opella Healthcare SAS (Sanofi Consumer Health Business) in October 2024 at 8.8x EV / EBITDA and 0.7x EV / Revenue. Separating consumer self-care from prescription operations is a recurring source of supply in this… May-2024 IAC, Inc. → Haleon plc n/a 2.2x 23.3x IAC, Inc. is recorded against Haleon plc in May 2024 at 23.3x EV / EBITDA and 2.2x EV / Revenue. The distance to the later entries on the same target is a reminder that one record is a data point rather than a band. Apr-2024 NA → PT Industri Jamu dan Farmasi Sido Muncul Tbk n/a 5.7x n/a PT Industri Jamu dan Farmasi Sido Muncul Tbk is recorded in April 2024 at 5.7x EV / Revenue. Branded consumer health outside the regulated generics channel is often marked on revenue, where the margin structure travels differently. Aug-2022 Thoma Bravo → Sandoz n/a 3.0x n/a Thoma Bravo is recorded against Sandoz in August 2022 at 3.0x EV / Revenue. A large generics platform with manufacturing footprint and geography attracts sponsor interest on a revenue basis when the portfolio mix is mid-transition.

  19. 19
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    Second page of the full precedent transaction list with disclosed terms, newest first.

    We continue the transaction list here, completing the twenty-five disclosed-term transactions shown across these two pages. The multiples shown remain on the LTM-at-announcement basis, not the CY2027E public basis used earlier in this report. Transactions without a disclosed value or multiple sit outside this list. This is the complete disclosed-terms record referenced throughout the report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 25 transactions with disclosed terms in this tier (54 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 63 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 29 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 25 transactions shown; the rest are in the companion workbook. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Dec-2021 Vimian Group AB → GlobalOne Pet Products LLC n/a n/a 8.8x Nov-2021 Francisco Partners → Sol-Gel Technologies n/a 3.4x 10.7x Mar-2021 Anixter International Inc. → Generic Rx Pharmaceuticals business n/a 11.7x 11.7x Nov-2020 Upjohn Inc. → Mylan N.V. n/a n/a 6.5x Jan-2020 ANI Pharmaceuticals, Inc. → Amerigen Pharmaceuticals Ltd. n/a 1.4x n/a Value shown as recorded in the filing; deal value unit unresolved. Sep-2018 Aurobindo Pharma Limited → Sandoz US dermatology business and generic US oral solids portfolio n/a 0.8x n/a Value shown as recorded in the filing; deal value unit unresolved. Jul-2018 Mayne Pharma Group Limited → Spear Pharmaceuticals, Inc. (generic Efudex) n/a 1.7x n/a Value shown as recorded in the filing; deal value unit unresolved. May-2018 Lannett Company, Inc. → Endo International plc (23 generic drugs) n/a 0.1x n/a Value shown as recorded in the filing; deal value unit unresolved. Sep-2017 CVC → Teva Women’s Health n/a 2.7x n/a Value shown as recorded in the filing; deal value unit unresolved.

  20. 20
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Methodology page setting out sources, assumptions and data-quality exclusions.

    We set out here how this analysis was built: the valuation basis used throughout, what was excluded and why, and where each underlying disclosure sits. A client can trace any figure in this deck to its source and the basis on which it was read. This page, together with the appendix, gives the full picture of what is included, what is excluded, and on what terms.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Generic and Non-Prescription Drugs and it clears the coverage gate with 7 of 10 companies (70%). EV / Revenue, P / E are carried as a cross-check. The set earns: 7 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 4 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 499 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (498) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  21. 21

    The Higher Prices in This Set Sit with the Faster-Growing Names.

    Closing page restating that the higher prices in this set sit with the faster-growing names.

    We close on the same line the data supports throughout: the higher prices in this set sit with the faster-growing names. The companion tables carry the full universe and source index for any figure a client wants to trace further.

    Everything on this page

    The Higher Prices in This Set Sit with the Faster-Growing Names. NeuraCap AI — Generic and Non-Prescription Drugs Coverage September 2026 · Prepared by NeuraCap AI · Confidential Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21

Sources and methodology

This report covers Generic and Non-Prescription Drugs (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Generic and Non-Prescription Drugs) with market data and consensus estimates as of September 28, 2026. The company universe is the 10 listed companies whose core business is Generic and Non-Prescription Drugs according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Amphastar Pharmaceuticals, Inc. (AMPH), Amneal Pharmaceuticals, Inc. (AMRX), Kenvue Inc. (KVUE), Liquidia Corporation (LQDA), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO), Dr. Reddy's Laboratories Limited (RDY), Regencell Bioscience Holdings Limited (RGC), Teva Pharmaceutical Industries Limited (TEVA), Viatris Inc. (VTRS). The market map groups them by business vertical — Specialty and complex generics manufacturers: 7 companies (TEVA, VTRS, RDY, AMRX, PRGO, RGC, AMPH); Branded off-patent and prescription generic portfolios: 2 companies (LQDA, PBH); Consumer self-care and personal care brand portfolios: 1 company (KVUE). 7 of the 10 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Generic and Non-Prescription Drugs (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Generic and Non-Prescription Drugs) with market data and consensus estimates as of September 28, 2026. The company universe is the 10 listed companies whose core business is Generic and Non-Prescription Drugs according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Amphastar Pharmaceuticals, Inc. (AMPH), Amneal Pharmaceuticals, Inc. (AMRX), Kenvue Inc. (KVUE), Liquidia Corporation (LQDA), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO), Dr. Reddy's Laboratories Limited (RDY), Regencell Bioscience Holdings Limited (RGC), Teva Pharmaceutical Industries Limited (TEVA), Viatris Inc. (VTRS). The market map groups them by business vertical — Specialty and complex generics manufacturers: 7 companies (TEVA, VTRS, RDY, AMRX, PRGO, RGC, AMPH); Branded off-patent and prescription generic portfolios: 2 companies (LQDA, PBH); Consumer self-care and personal care brand portfolios: 1 company (KVUE). 7 of the 10 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

4 records failed a validation gate and never feed a statistic in this report (4 excluded from aggregate). Each exclusion, with its reason: LQDA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LQDA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · PRGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · VTRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Generic and Non-Prescription Drugs and it clears the coverage gate with 7 of 10 companies (70%). EV / Revenue, P / E are carried as a cross-check. The set earns: 7 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 7 of 10 companies; EV / rEVenue: 9 of 10 companies; P/E: 8 of 10 companies.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥10.5x, Core 7.4x–10.5x, Discount <7.4x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 7.5x = median(ev_ebitda CY2027E) (7 rated companies) · 12.3x = median(ev_ebitda CY2027E) within Premium tier (n=2) · 7.5x = median(ev_ebitda CY2027E) within Core tier (n=4) · 6.9x = median(ev_ebitda CY2027E) within Discount tier (n=1) · 9.0x = median(ev_ebitda CY2027E) | growth ≥ 5% (n=4) · 7.4x = median(ev_ebitda CY2027E) | growth < 5% (n=3) · 7.5x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 26% (n=4) · 10.6x = median(ev_ebitda CY2027E) | EBITDA margin < 26% (n=3) · 33% = median Rule of 40 score (revenue growth + EBITDA margin) (n=7)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Generic and Non-Prescription Drugs recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 54 transactions were recorded for this industry; 25 are shown. 29 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 29 × deal value unit unresolved; 22 × no evidence record; 6 × duplicate precedent id; 6 × divestiture roles reassigned. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 503 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

More coverage in Health Care

Want this analysis for a company in Generic and Non-Prescription Drugs?

Company valuation reports run the same method against a single business — public or private.

Get your reportTalk to advisory